Table 4.
Adherence and Persistence Outcomes Measured During 6-Month Follow-Up Period
| Demographics | Propensity score matched | Unmatched | ||||
|---|---|---|---|---|---|---|
| Patients using sulfonylurea (N = 13,657) | Patients using SGLT-2 inhibitor (N = 13,657) | P value for matched cohorts | Patients using sulfonylurea (N = 25,490) | Patients using SGLT-2 inhibitor (N = 17,724) | P value for unmatched cohorts | |
| PDC by index medication class (adherence),a mean (SD) | 71.8% (29.3%) | 75.6% (27.5%) | <.0001 | 72.1% (29.6%) | 75.8% (27.3%) | <.001 |
| PDC ≥80% | 53.9% | 61.4% | <.0001 | 54.7% | 61.8% | <.001 |
| Nonpersistent with index medication classb | 31.1% | 23.9% | <.0001 | 31.4% | 23.6% | <.001 |
| Days to nonpersistence among patients who discontinued, mean (SD) | 80.7 (50.8) | 77.0 (48.7) | <.0001 | 80.6 (50.3) | 77.2 (48.6) | <.001 |
a
Proportion of days covered calculated as the number of days with index medication class “on hand” divided by 180 days and capped at 100%.
b
Nonpersistent is defined as the presence of a >60-day gap past the end of the previous fill's days' supply (fill date plus days' supply).
PDC indicates proportion of days covered; SD, standard deviation; SGLT-2, sodium-glucose cotransporter 2.